Remedy Robotics has raised US$62 million in Series B funding. The San Francisco company develops AI-enabled robotic systems for cardiovascular and endovascular care. DCVC led the round, with UC Investments, Skip Capital, and Hostplus joining.
Trial and approval plans
The capital will support a planned pivotal clinical trial with the University of California. Remedy also aims to advance FDA approval for neurovascular intervention. It will place prototype N1 Systems with clinical partners, including SVIN Mission Thrombectomy and the Australian Stroke Alliance.
Backing and clinical reach
Existing investors Build Collective by Tony Fadell, Blackbird, Divergent Capital, and KdT Ventures also increased their support. Remedy now works with more than 100 hospitals worldwide. In October 2025, it completed the world's first remote neurointerventional procedures using the N1 System.
What the N1 System does
The N1 System analyzes preoperative imaging and simulates cases in advance. It provides real-time 3D-2D image registration and can complete endovascular procedures robotically. The platform is designed for on-site, remote, or autonomous operation.
The company will use the funding to advance toward FDA approval and develop additional features, including full autonomy. It also plans to prepare for clinical trials across the UC network. The N1 System remains under development and is not currently available for sale or clinical use.